ADC Therapeutics S.A. (ADCT): תחזית צמיחת רווחים לשנה הבאה

The investment potential of ADC Therapeutics (ADCT) is based on advanced targeted antibody developments and the availability of approved drugs. The projected change in earnings per share for the coming year, presented as a time series on the GURU.Markets chart, shows that the value remains at 8.00. This is supported by the market penetration of the lymphoma therapy Zynlonta and the company's high standing among specialized hematologists.
פילוחים אנליטיים של חברת ADC Therapeutics

The commercial success of Zynlonta in lymphoma therapy establishes a foundation for revising the financial expectations of ADC Therapeutics (ADCT). The price action regarding future earnings per share growth reflects the analysts' consensus forecast for next year's EPS changes. While the positive trend of this indicator confirms market optimism, excessive peaks signal a risk of overpayment. Steady growth of this metric at moderate levels confirms the asset's investment attractiveness.